Correlation Between Metabolic Syndrome And Clinical Pathological Characteristics Of Tumors In Patients With Prostate Cancer

Objective:This article analyzes the relationship between metabolic abnormalities related to prostate cancer patients and the clinicopathological characteristics of the tumor,and explores the impact of metabolic syndrome on the occurrence,progression,and biochemical recurrence of prostate cancer,providing some help and guidance for the prevention and treatment of clinical prostate cancer.Methods:Retrospective analysis of the clinical data of 204 patients diagnosed with prostate cancer after(robot-assisted)laparoscopic radical prostatectomy from January1,2017 to December 31,2019 in our hospital,and the clinical data of 204 male control patients in the same age group who were randomly selected by the physical examination center for healthy physical examination.According to the diagnostic criteria of Metabolic syndrome(MS),the study subjects were divided into the MS group / non-MS group.Analyzing the incidence of prostate cancer in the MS and non-MS groups,and study whether MS is related to the risk of prostate cancer;then assess whether the differences between clinical pathological factors such as testosterone levels,high PSA(PSA> 20 ng / ml),high Gleason score(> 7 points),high TNM stage(≥T3 or N1 or M1)in the MS / non-MS population in the experimental group are statistically significant,and further subgroup analysis of the relationship between metabolic syndrome components and high PSA,high Gleason score and high TNM stage was performed.Finally,the difference in the risk of no biochemical recurrence after radical resection was analyzed to explore the impact of metabolic syndrome on the occurrence,progression and prognosis of prostate cancer.Results:Among 204 patients with prostate cancer,48 patients(23.5%)had metabolic syndrome,72 had high Gleason score(35.3%),113 had high PSA(55.4%),87 hadhigh TNM stage(42.6%),and 204 were healthy There were 30 cases of metabolic syndrome(14.7%)in the control group.Statistical analysis found that metabolic syndrome was closely related to the risk of prostate cancer(P = 0.02).In addition,among prostate cancer patients,MS / non-MS populations had statistically significant differences in testosterone levels,postoperative pathological Gleason score and TNM stage(P <0.05),and there was no significant difference in the maximum PSA level(P> 0.05).The diagnostic factors of MS,hypertension and abnormal blood glucose were positively correlated with high Gleason score and high TNM stage after operation(P <0.05,the corresponding OR value and 95% confidence interval were greater than 1).There was a statistically significant difference in the risk of no biochemical recurrence between MS and non-MS patients(P = 0.001).Conclusion:1.Metabolic syndrome is closely related to the risk of prostate cancer.Patients with metabolic syndrome have a significantly increased risk of prostate cancer.2.Testosterone levels in prostate cancer patients with metabolic syndrome are relatively low,but the tumor pathological stage is often late,the degree of malignancy is higher,and it is more likely to progress;the abnormal blood glucose and hypertension of the components of the metabolic syndrome are the progression of prostate cancer Independent risk factors.3.Prostate cancer patients with metabolic syndrome have a significantly increased risk of biochemical recurrence after radical surgery.In summary,metabolic syndrome and its various metabolic disorder factors are closely related to the risk of prostate cancer occurrence and progression.Reasonable intervention management of metabolic disorder may bring some new ideas for the prevention,treatment and prognosis management of prostate cancer.